Smell and Memory: How Early Brain Changes May Predict Parkinson’s Decline

A team of researchers recently followed a group of 97 people who had just been diagnosed with early-stage Parkinson’s disease to see how their brains and thinking abilities changed over four years. The study focused on brain regions linked to our sense of smell, such as the amygdala, insula, orbitofrontal cortex, and thalamus, because a reduced sense of smell is one of the earliest and most common warning signs of Parkinson’s. At the start of the study and then again at two and four years, the participants had brain scans and cognitive tests. The researchers also took blood and spinal fluid samples to measure various biological markers, including one called neurofilament light chain, or NfL for short. NfL is a protein released when nerve cells are damaged, and high levels are often seen in conditions that involve nerve loss. Over time, the brain scans revealed that several smell-related regions gradually shrank or thinned, showing that Parkinson’s slowly affects areas beyond those controlling movement. The thalamus, a hub for processing sensory information, showed particularly strong signs of deterioration in both sides of the brain. The insula, a region involved in emotional and sensory processing, also displayed subtle changes in its structure. Perhaps the most important finding was that these early brain changes predicted how people would fare later. Those who already showed structural changes in their scans tended to experience greater cognitive decline as the years went on. The same pattern was seen in people who had higher NfL levels in their blood or spinal fluid at the beginning of the study—they were more likely to see their memory and thinking abilities worsen over time. This matters because Parkinson’s is not only about tremors and stiffness. Many people also struggle with changes in mood, attention, memory, and decision-making as the disease progresses. Detecting these early warning signs could make a huge difference. If doctors can combine brain scans with biological markers to identify who is likely to decline faster, they can adapt treatment plans sooner and tailor care more precisely. The study did have some limitations. Some participants began Parkinson’s medication during the research period, which might have influenced their results. And while NfL proved useful as a predictor, other markers such as tau, amyloid, and alpha-synuclein did not show the same link to decline. The brain imaging also provides only an indirect view of what is happening—it shows changes in structure but not exactly which cells are affected or how inflammation might be involved. Still, the results offer a hopeful step toward more accurate ways to track Parkinson’s progression. The fact that changes in smell-related brain regions appear so early suggests that the disease’s effects spread far beyond the movement centres long before symptoms become obvious. By combining imaging and fluid markers, researchers may one day be able to predict who is most at risk of cognitive decline and intervene before those changes take hold.